Changsha-headquartered pharmaceutical company Hunan Nucien Pharmaceutical Co., Ltd, is targeting an initial public offering (IPO) on China’s Nasdaq-like STAR Market to raise about 1.2 billion yuan ($175 million).
State-owned Hunan Nucien intends to offer 35 million shares at a price of 34.94 yuan ($4.98) apiece, according to the pricing terms finalised on March 13.
